Scientific Sessions 2024  /  Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations  /  Discussant: OLE & HELIOS-B
Logo

American Heart Association

  20
  0

Final ID:

Discussant: OLE & HELIOS-B

  • Grogan, Martha  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Kittleson, Michelle  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Nair, Ajith  ( Baylor College of Medicine , Houston , Texas , United States )
  • Grodin, Justin  ( UT SOUTHWESTERN , Dallas , Texas , United States )
  • Ambardekar, Amrut  ( , Aurora , Colorado , United States )
    • Author Disclosures:
    Martha Grogan: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alnylam:Active (exists now) ; Advisor:NovoNordisk:Active (exists now) ; Advisor:AztraZeneca:Active (exists now) ; Consultant:Janssen:Active (exists now) ; Research Funding (PI or named investigator):Janssen:Past (completed) ; Research Funding (PI or named investigator):NovoNordisk:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Past (completed) ; Research Funding (PI or named investigator):Eidos:Active (exists now) | Michelle Kittleson: DO NOT have relevant financial relationships | Ajith Nair: DO have relevant financial relationships ; Speaker:Janssen:Active (exists now) ; Consultant:Abbott:Past (completed) ; Advisor:Gossamer Bio:Past (completed) ; Speaker:Impulse Dynamics:Past (completed) | Justin Grodin: DO have relevant financial relationships ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Consultant:Sarepta:Past (completed) ; Consultant:Tenax:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Alexion:Active (exists now) ; Consultant:Alnylam:Past (completed) ; Consultant:Astra-Zeneca:Active (exists now) ; Consultant:Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Eidos/BridgeBio:Past (completed) | Amrut Ambardekar: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations

Monday, 11/18/2024 , 09:45AM - 11:00AM

Featured Science

More abstracts on this topic:
Discussant: VALOR-HCM

Deswal Anita, Ho Jennifer, Ho Carolyn, Day Sharlene

Impact of vutrisiran on outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial

Fontana Marianna, Maurer Mathew, Gillmore Julian, Bender Shaun, Aldinc Emre, Eraly Satish, Jay Patrick, Solomon Scott

More abstracts from these authors:
5 Key Lessons learned about Cardiac Amyloidosis in the last 10 years and what remains to be learned. 10 minutes

Maurer Mathew, Ambardekar Amrut

The Final Battle: Advanced Heart Failure and AF - HF Top 5 Take Aways

Ambardekar Amrut, Kittleson Michelle

You have to be authorized to contact abstract author. Please, Login
Not Available